BioSyent's Q3 and YTD 2024 financial results show sales growth, increased income, and strategic investments.

From Globe Newswire: 2024-11-20 08:00:00

BioSyent Inc. reported its financial results for Q3 and YTD 2024, with Canadian Pharma Sales up 12% and Total Company Sales up 8% in Q3. EBITDA was down 2%, while Net Income After Taxes increased by 13%. The company acquired Tibelia® global rights, expecting revenue in Q1 2025. CEO René Goehrum expressed satisfaction with the growth and investments made.

BioSyent’s total Company sales reached a record high in Q3 2024, growing by 8% compared to Q3 2023. Year-to-date, total Company sales, EBITDA, and Net Income After Taxes increased by 13%. The company made investments in acquiring Tibelia® and developing new products, aiming for long-term growth and portfolio diversification. CEO Goehrum looks forward to continued progress in 2025.

In Q3 2024, BioSyent acquired Tibelia® and reported the highest quarterly total Company sales. Year-to-date, total Company sales grew by 13%, with EBITDA increasing by 12%. The company also repurchased 162,300 common shares and paid quarterly dividends. CEO Goehrum highlighted ongoing growth and investments made for future revenue and EBITDA.

BioSyent Inc., a specialty pharmaceutical company focused on innovative products, released its financial results for Q3 and YTD 2024. Key highlights include 12% growth in Canadian Pharma Sales and 8% growth in Total Company Sales in Q3. The company also acquired Tibelia® global rights, aiming for revenue and EBITDA growth in 2025.



Read more at Globe Newswire:: BioSyent Releases Financial Results for Q3 and YTD 2024